Further comparative analysis reveals that patients with high TCR signaling are unlikely to benefit from XELOX, but instead the combination of anti-HER2-based therapy; while the activation of ECM and the downstream PI3K-AKT pathway impairs the anti-tumor effect of trastuzumab. Here, ERBB2 is linked to neoplasm.